908 Devices’ (MASS) Sell (D-) Rating Reaffirmed at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of 908 Devices (NASDAQ:MASS) in a research report released on Tuesday morning,Weiss Ratings reports.

Separately, Stephens restated an “overweight” rating and set a $6.00 target price on shares of 908 Devices in a report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.33.

908 Devices Stock Performance

MASS stock opened at $3.63 on Tuesday. The company has a market capitalization of $128.25 million, a PE ratio of -2.05 and a beta of 0.30. 908 Devices has a one year low of $1.81 and a one year high of $7.48. The company’s 50 day moving average price is $3.25 and its two-hundred day moving average price is $2.96.

Institutional Trading of 908 Devices

Several large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. boosted its holdings in 908 Devices by 14.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company’s stock valued at $765,000 after acquiring an additional 28,015 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of 908 Devices by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 567,788 shares of the company’s stock valued at $1,970,000 after purchasing an additional 6,634 shares in the last quarter. State Street Corp increased its position in shares of 908 Devices by 1.2% during the third quarter. State Street Corp now owns 479,044 shares of the company’s stock valued at $1,662,000 after buying an additional 5,704 shares during the period. Barclays PLC raised its stake in 908 Devices by 452.7% in the third quarter. Barclays PLC now owns 46,214 shares of the company’s stock worth $160,000 after buying an additional 37,853 shares in the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new stake in 908 Devices in the fourth quarter worth about $52,000. 88.06% of the stock is owned by institutional investors.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.